Member Info for Energyshares

Apre excellent post.

Yawn……..wynbore…..

Wiggly great post dont forget Point & Astrea should be on that list.
1. Precision?
2. LG chem?
3. Affyxell
4 Point Bio
5 Astrea

And if Precision is validated to work then
TMac comes into play.

Rippers the Basher Bounty Hunter.
LSE should be paying you a wage for exposing all these rat traders.
Keep it going Rippers :) :)

They need phase 1b to start ASAP and I don’t think they can start it without phase 1a data, so I would guess September.

LG Chem will now proceed with Investigational New Drug (IND) enabling studies for Affimer PD-L1 antagonist programme.
LG being very clever just in case of a Avacta take over approach.

I bet they have the legals water tight to hold on to this licence.

Yes Timster
But AS gets to speak in 80% of the interview and Giles 20%.

But with Paul Hill it’s Paul 80% and AS 20%
And SP still tanks :):)

Please Timster not Paul Hill we have tanked after every interview with him.

“Bring Back Giles”

Avacta's Safety Data Monitoring Committee (SDMC), comprised of clinicians currently recruiting patients, has completed its review of the safety data from the second cohort dosed with AVA6000 at 120mg/m2 in the ongoing Phase I trial. Following this review, the SDMC has recommended that the clinical trial continues as planned and escalates to the next dose of AVA6000 at 160mg/m2.

So without moving to DE2
Avacta are sitting on something that’s miles better than what’s on the market now.
The market has to wake up to this soon.

Emerging means something close to sprouting — when you think of this word, think "growing."

Let’s hope the SP starts to grow :)

That’s the sentence we need Rippers

Poor Wress

Neil Bell, Chief Development Officer of Avacta added:
“The recommendation from the Safety Data Monitoring Committee to initiate dosing in Cohort 3 with 160mg/m2 of AVA6000 is an endorsement of the emerging safety and tolerability profile in the patients enrolled in this study to date.

Doxorubicin (Adriamycin) is one of the most powerful chemotherapy drugs ever invented. It can kill cancer cells at every point in their life cycle, and it's used to treat a wide variety of cancers. Unfortunately, the drug can also damage heart cells, so a patient can't take it indefinitely.

So there is no way the SDMC would allow this trial to continue with this poison just circulating the body,if it is releasing it has to be in the tumour or again they would stop the trial.

Now stop and think what this SDMC, which are independent from Avacta have now allowed to happen.
“one of the most powerful chemotherapy drugs ever invented.” they have allowed 50% more than can be administrated of this poison into patients.
If this leaks anywhere else than the tumour it would probably result in death.

In the next few weeks a 2nd DE will be allowed.

This could propel little Avacta into the big league.

The Safety Data Monitoring Committee (SDMC), comprised of clinicians currently recruiting patients, has completed its review of the safety data from the first cohort dosed with AVA6000 at 80mg/m2 in the ongoing Phase I trial. Following this review, the SDMC has recommended that the clinical trial continues as planned and escalates to the next dose of AVA6000 at 120mg/m2.

GLA

Poor thing ramped so much then fell the other side of the fence….. :)

Ok Derek
https://m.youtube.com/watch?v=gi-xZ2yr0tc

Hi Richob
Thanks ,but I was just doing the history of the AVA6000 trial to date.
So much noise on here at the moment it would be hard for new investors to see this info.

But your right so many more shots on goal going on.

:)

Gadgie
Please use,just trying to inform new investors and move the trolls agenda off the board.

For new investors a little history of last 11 months.

Aug 21
Trial starts 1st patient dosed with AVA6000.
Appointment of Dr Fiona McLaughlin as Chief Scientific Officer.
Independent safety committee meets twice
trial continues.
Sep 21
The three new members of the SAB are Professor James Spicer MB., BA., PhD., FRCP, Professor Krishnan Komanduri, MD, and Dr Ste´phane Champiat MD, PhD.
Independent safety committee meets twice
trial continues.
Oct 21
Independent safety committee meets twice
trial continues.
Nov 21
FDA Approval of its Investigational New Drug (IND) Application for AVA6000
Independent safety committee meets twice
trial continues.
Dec21
Independent safety committee meets twice
trial continues.
Jan 22
Avacta Selects Second pre|CISIONTM Pro-drug Candidate for development.
Independent safety committee meets twice
trial continues.
Feb 22
Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin.
CEO Alastair Smith and Chief Scientific Officer Fiona McLaughlin announce remarkable consistent data and that biopsies will be performed even though they are not needed for this part of trial.
Independent safety committee meets twice
trial continues.
Mar 22
Top American Oncologist Christina Coughlin joins Avacta board.
Avacta sells Animal health division.
Independent safety committee meets twice
trial continues.
April 22
Avacta to presents pre-clinical data on AVA6000 at the American Association for Cancer Research Annual Meeting
Independent safety committee meets twice
trial continues.
Glasgow starts recruiting with Sheffield and Newcastle and USA also getting ready to recruit patients.
May 22
Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus
Independent safety committee meets twice
trial continues. Jupiter starts to reduce their short.
June 22
Independent safety committee meets twice
trial continues.

GLA

Well Merck know about AVA6000 and must be following the trial closely.

5.1.5. Novel Anthracyclines: AVA6000
A first-in-human study has been initiated with AVA600 for patients with locally advanced and/or metastatic solid tumors including CRC (NCT04969835). This promising phase I study will evaluate the safety, tolerability, and pharmacokinetics of AVA6000, a modified pro-drug version of doxorubicin that remains inactive until it reaches the malignant microenvironment. There, once activated as doxorubicin, it attacks malignant cells, triggering multifactorial toxicity that involves oxidative stress by induction of O2•- and H2O2, DNA/RNA damage by binding and blocking topoisomerases, autophagy and apoptosis induction by calcium leakage and calcium channel dysregulation, and mitochondrial dysfunction through •NO release [126].

Funding
This research was funded by Merck Salud Foundation project award (2019) given to A.S. (Antonieta Salud); by Merck Salud Foundation project award (2021) given to R.M.; by the University and Research Grants Management Agency (AGAUR) of the Catalonia Government (emergent research group recognition award (2017SRG1620) given to M.A.S.; and by AGAUR (2021FIB00025) given to I.H. The 2020 Miguel Servet fellowship from the Instituto de Salud Carlos III (Spanish National Institute of Health) under Grant CP20/00039 was given to A.S. (Antonieta Salud). The research was supported by the CERCA Program of the Generalitat de Catalunya and the IRBLleida (Fundació Pifarré).

https://www.mdpi.com/2072-6694/13/20/5037/htm

:)